Cytokine release-mediated anti-tumor response

"Cytokine release-mediated anti-tumor response" is **not a single molecule or receptor**, but rather describes a biological process where the immune system—particularly activated T cells—releases large amounts of pro-inflammatory cytokines in response to tumor antigens. This phenomenon underlies both therapeutic efficacy and significant toxicity in modern cancer immunotherapies such as CAR T-cell therapies and bispecific antibodies. While robust cytokine signaling can drive effective tumor killing by recruiting and activating various immune effector cells, excessive or uncontrolled release leads to **cytokine release syndrome**—a potentially life-threatening condition characterized by fever, hypotension, organ dysfunction, and systemic inflammation. The term does not refer to a discrete druggable entity but rather an emergent property of complex cellular interactions within the tumor microenvironment or following potent immunotherapeutic interventions[1][2]. In summary: "Cytokine release-mediated anti-tumor response" is not itself a canonical molecular target; it refers instead to an important biological process central to both cancer immunity and treatment-related toxicities.

Other names

Cytokine release syndromeCRScytokine stormcytokine-mediated anti-tumor response (context-dependent)

*Not applicable as a direct molecular target.* Drugs listed above act by engaging immune cells or depleting specific lymphocyte populations, which can result in massive cytokine release as an adverse effect[2].